Spero Therapeutics (SPRO) Return on Sales (2016 - 2025)
Historic Return on Sales for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 1.36%.
- Spero Therapeutics' Return on Sales fell 400.0% to 1.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.07%, marking a year-over-year decrease of 11300.0%. This contributed to the annual value of 1.43% for FY2024, which is 16900.0% down from last year.
- As of Q3 2025, Spero Therapeutics' Return on Sales stood at 1.36%, which was down 400.0% from 0.12% recorded in Q2 2025.
- Spero Therapeutics' 5-year Return on Sales high stood at 2.13% for Q4 2022, and its period low was 14.57% during Q1 2022.
- Over the past 5 years, Spero Therapeutics' median Return on Sales value was 2.36% (recorded in 2025), while the average stood at 3.93%.
- Examining YoY changes over the last 5 years, Spero Therapeutics' Return on Sales showed a top increase of 121200bps in 2022 and a maximum decrease of -119200bps in 2022.
- Over the past 5 years, Spero Therapeutics' Return on Sales (Quarter) stood at 9.99% in 2021, then surged by 121bps to 2.13% in 2022, then tumbled by -65bps to 0.75% in 2023, then crashed by -281bps to 1.36% in 2024, then fell by 0bps to 1.36% in 2025.
- Its Return on Sales was 1.36% in Q3 2025, compared to 0.12% in Q2 2025 and 2.36% in Q1 2025.